Floatz logo

Defosbarasertib

SCLC, Recurrent

AstraZenecaSmall moleculePhase 2Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

290 Active assets in the SCLC, Recurrent cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Defosbarasertib is also rated in:

small cell lung carcinomaDormant
C
Indicative ·
39 / 100
View asset →
Advanced Solid TumoursDormant
C
Indicative ·
35 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →